Fluocinonide

Fluocinonide
Clinical data
Trade names	Lidex
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a601054
Pregnancy; category	C;
Routes of; administration	topical
ATC code	C05AA11 (WHO) D07AC08 (WHO);
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Metabolism	hepatic
Identifiers
	IUPAC name 6α,9-difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone,21-acetate;
CAS Number	356-12-7 ;
PubChem CID	9642;
IUPHAR/BPS	7078;
DrugBank	DB01047 ;
ChemSpider	9265 ;
UNII	2W4A77YPAN;
KEGG	D00325 ;
ChEMBL	ChEMBL1501 ;
CompTox Dashboard (EPA)	DTXSID8045307 ;
ECHA InfoCard	100.005.998
Chemical and physical data
Formula	C26H32F2O7
Molar mass	494.532 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC(=O)[C@]45OC(O[C@@H]5C[C@@H]2[C@@]4(C[C@H](O)[C@]3(F)[C@]/1(/C=C\C(=O)\C=C\1[C@@H](F)C[C@@H]23)C)C)(C)C)C;
	InChI InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1 ; Key:WJOHZNCJWYWUJD-IUGZLZTKSA-N ;
	(verify)

Fluocinonide (Fluonex, Lidex, Lidex-E, Lonide, Lyderm, Metosyn and Vanos)[1] is a potent glucocorticoid used topically as an anti-inflammatory agent for the treatment of skin disorders such as eczema and seborrhoeic dermatitis. It relieves itching, redness, dryness, crusting, scaling, inflammation, and discomfort.

The usual prescription concentration is 0.05% as a topical cream, ointment, solution, or gel. The application area should normally not be covered after application. In certain cases, the physician may recommend the use of an occlusive dressing after application to increase the rate and depth of absorption. The frequency of application depends on the condition being treated and the area affected, but most often it should be applied 2 to 4 times a day.[2]

Fluocinonide ranks as a "high-potency" (second-highest rank) topical corticosteroid. Minimal amounts should be used for a minimal length of time to avoid the occurrence of adverse effects.

Fluocinonide should not be used if infection is present. It should not be applied to the eyes or to sensitive areas such as the genitals or anus.

A common potential adverse effect is skin atrophy (thinning of the skin). Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis (HPA) suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Fluocinonide should be used with caution when treating children, pregnant women, nursing mothers, and anyone using the medication for longer than two weeks.

Fluocinonide is used in veterinary medicine. It is a treatment for allergies in dogs.[3] Natural systemic cortisol concentrations can be suppressed for weeks after one week of topical exposure.[4]

References

MedlinePlus Drug Information: Fluocinonide Topical
"Fluocinonide Topical". MedlinePlus. US National Library of Medicine, NIH. Retrieved 6 March 2014.
Dog Allergies www.squidoo.com/dogallergy
Zenoble RD, Kemppainen RJ (September 1987). "Adrenocortical suppression by topically applied corticosteroids in healthy dogs". Journal of the American Veterinary Medical Association. 191 (6): 685–8. PMID 2824410.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] MedlinePlus Drug Information: Fluocinonide Topical

[2] "Fluocinonide Topical". MedlinePlus. US National Library of Medicine, NIH. Retrieved 6 March 2014.

[3] Dog Allergies www.squidoo.com/dogallergy

[4] Zenoble RD, Kemppainen RJ (September 1987). "Adrenocortical suppression by topically applied corticosteroids in healthy dogs". Journal of the American Veterinary Medical Association. 191 (6): 685–8. PMID 2824410.

Fluocinonide

See also

References